|Application ||WB, E|
|Other Accession||NP_001096, 4501895|
|Calculated MW||57153 Da|
|Application Notes||ACVR1 antibody can be used for detection of ACVR1 by Western blot at 1 µg/mL.|
|Target/Specificity||ACVR1; At least four isoforms of ACVR1 are known to exist. This antibody is predicted to have no cross-reactivity to ACVR1B or ACVR1C.|
|Reconstitution & Storage||ACVR1 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.|
|Precautions||ACVR1 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for activin. May be involved for left-right pattern formation during embryogenesis (By similarity).|
|Cellular Location||Membrane; Single-pass type I membrane protein|
|Tissue Location||Expressed in normal parenchymal cells, endothelial cells, fibroblasts and tumor-derived epithelial cells|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
ACVR1 Antibody: Activins are dimeric growth and differentiation factors which belong to the transforming growth factor-beta (TGF-beta) superfamily of structurally related signaling proteins. Activins signal through a heteromeric complex of receptor serine kinases which include at least two type I and two type II receptors. Unlike ACVR1B and ACVR1C, ACVR1, also known as activin receptor-like kinase 2 (ALK2), can not transduce activin-mediated signaling, but will transduce BMP and Mullerian inhibiting substance (MIS) group signaling. It is thought that ACVR1 also inhibits activin signaling by blocking the binding of activin to its type II receptor. Recent studies indicate that genetic variation in ACVR1 is associated with polycystic ovary syndrome, suggesting that ACVR1 signaling contributes to disturbed folliculogenesis in these patients.
Tsuchida K, Sawchenko PN, Nishikawa S, et al. Molecular cloning of a novel type I receptor serine/threonine kinase for the TGF beta superfamily from rat brain. Mol. Cell. Neurosci.1996; 76:467-78.
ten Dijke P, Yamashita H, Sampath TK, et al. Identification of type I receptors for osteogenic protein-1 and bone morphogenetic protein-4. J. Biol. Chem.1994; 269:16985-8.
Clarke TR, Hoshiya Y, Yi SE, et al. Mullerian inhibiting substance signaling uses a BMP-like pathway mediated by ALK2 and induces Smad6 expression. Mol. Endocrinol.2001; 15:946-59.
Renlund N, O’Neill FH, Zhang L, et al. Activin receptor-like kinase-2 inhibits activin signaling by blocking the binding of activin to its type II receptor. J. Endocrinol.2007; 195:95-103.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.